Limitations of CAR T-cell therapy for DLBCL

Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, shares her thoughts on immunotherapies for relapsed diffuse large B-cell lymphoma (DLBCL). Whilst autologous chimeric antigen receptor (CAR) T-cells have been approved to treat DLBCL, they take a long time to be manufactured, they cannot be manufactured everywhere, and not all patients respond well to CAR T-cell therapy. It is therefore important to develop other effective therapies. Dr Phillips explains that bi-specific T-cell engagers (BiTEs) represent a promising alternative to CAR T-cell therapy. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.